Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay

被引：1
|
作者：
Parikh, A. [1 ]
van Seventer, E. [2 ]
Boland, G. [1 ]
Siravegna, G. [1 ]
Hartwig, A. [3 ]
Jaimovich, A. [4 ]
Raymond, V. M. [5 ]
Talasaz, A. [6 ]
Corcoran, R. B. [7 ]
机构：
[1] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[3] Guardant Hlth Inc, Res & Dev, Redwood City, CA USA
[4] Guardant Hlth Inc, Bioinformat, Redwood City, CA USA
[5] Guardant Hlth Inc, Med Affairs, Redwood City, CA USA
[6] Guardant Hlth Inc, Redwood City, CA USA
[7] MGH Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419P
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [1] A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
    Parikh, Aparna Raj
    Van Seventer, Emily E.
    Boland, Genevieve Marie
    Hartwig, Anna
    Jaimovich, Ariel
    Raymond, Victoria M.
    Talasaz, AmirAli
    Corcoran, Ryan Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
    Parikh, Aparna R.
    Van Seventer, Emily E.
    Siravegna, Giulia
    Hartwig, Anna, V
    Jaimovich, Ariel
    He, Yupeng
    Kanter, Katie
    Fish, Madeleine G.
    Fosbenner, Kathryn D.
    Miao, Benchun
    Phillips, Susannah
    Carmichael, John H.
    Sharma, Nihaarika
    Jarnagin, Joy
    Baiev, Islam
    Shah, Yojan S.
    Fetter, Isobel J.
    Shahzade, Heather A.
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Dubois, Jon S.
    Franses, Joseph W.
    Giantonio, Bruce J.
    Goyal, Lipika
    Klempner, Samuel J.
    Nipp, Ryan D.
    Roeland, Eric J.
    Ryan, David P.
    Weekes, Colin D.
    Wo, Jennifer Y.
    Hong, Theodore S.
    Bordeianou, Liliana
    Ferrone, Cristina R.
    Qadan, Motaz
    Kunitake, Hiroko
    Berger, David
    Ricciardi, Rocco
    Cusack, James C.
    Raymond, Victoria M.
    Talasaz, AmirAli
    Boland, Genevieve M.
    Corcoran, Ryan B.
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5586 - 5594
  • [3] Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence
    Janni, Wolfgang
    Huober, Jens
    Braun, Tatjana
    Mueller, Volkmar
    Fink, Angelina
    de Gregorio, Amelie
    Rack, Brigitte
    Friedl, Thomas W.
    Wiesmueller, Lisa
    Pantel, Klaus
    Rich, Thereasa
    Parsana, Princy
    Zotenko, Elena
    Zhang, Shile
    Huesmann, Sophia
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
    Janni, W.
    Rack, B.
    Friedl, T. W. P.
    Hartkopf, A. D.
    Wiesmueller, L.
    Pfister, K.
    Mergel, F.
    Fink, A.
    Braun, T.
    Mehmeti, F.
    Uhl, N.
    De Gregorio, A.
    Huober, J.
    Fehm, T.
    Mueller, V.
    Rich, T. A.
    Dustin, D. J.
    Zhang, S.
    Huesmann, S. T.
    ESMO OPEN, 2025, 10 (04)
  • [5] Multiomic, plasma-only ctDNA NGS assay for minimal residual disease (MRD) detection in solid tumors.
    Kurata, Jessica
    Price, Kristin Sedgwick
    Banks, Kimberly
    Zotenko, Elena
    Hite, Dustin
    Cheng, Donavan
    Parsana, Princy
    Ju, Jin Hyun
    Dinman, Tara
    Miao, Zong
    Talasaz, AmirAli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Clinician utilization of a plasma-only, multiomic minimal residual disease (MRD) assay in 2,000 consecutive patients with colorectal cancer (CRC).
    Pedersen, Katrina Sophia
    Bucheit, Leslie A.
    Tan, Benjamin R.
    Hu, Zishuo Ian
    Shusterman, Michael
    Weipert, Caroline
    Banks, Kimberly
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15586 - E15586
  • [7] Multiomic, Plasma-Only ctDNA NGS Assay Developed for Minimal Residual Disease (MRD) Detection in Early-Stage NSCLC
    Kurata, J.
    Price, K.
    Banks, K.
    Zotenko, E.
    Dinman, T.
    Parsana, P.
    Miao, Z.
    Ju, J.
    Hite, D.
    Cheng, D.
    Talasaz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S952 - S953
  • [8] Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
    Chakrabarti, Sakti
    Kasi, Anup Kumar
    Parikh, Aparna R.
    Mahipal, Amit
    CANCERS, 2022, 14 (13)
  • [9] Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
    Parikh, Aparna R.
    Chee, Bryant H.
    Tsai, Jill
    Rich, Thereasa A.
    Price, Kristin S.
    Patel, Sonia A.
    Zhang, Li
    Ibrahim, Faaiz
    Esquivel, Mikaela
    Van Seventer, Emily E.
    Jarnagin, Joy X.
    Raymond, Victoria M.
    Corvera, Carlos U.
    Hirose, Kenzo
    Nakakura, Eric K.
    Corcoran, Ryan B.
    Van Loon, Katherine
    Atreya, Chloe E.
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2964 - 2973
  • [10] Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in stage 1-3 colorectal cancer (CRC) in clinical practice
    Somer, B.
    Mehler, S.
    Hasenburg, A.
    Greene, H.
    Tauer, K.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S347 - S347
12345